All In Biotech

BLA 103792 · Genentech

Herceptin

Trastuzumab · Intravenous · HER2/neu Receptor Antagonist

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Sep 25, 1998

Approved uses

10

Original approval plus efficacy supplements

Registered trials

1,500

287 Phase 3, 274 recruiting

FAERS reports

68,519

58,724 serious, 8,254 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning Cardiomyopathy: Herceptin can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Herceptin for cardiomyopathy. ( 2.5 , 5.1 ) Infusion Reactions, Pulmonary Toxicity: Discontinue Herceptin for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. ( 5.2 , 5.4 ) Embryo-Fetal Toxicity: Exposure to Herceptin during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of...

What it is approved for

From the label in effect May 29, 2026.

Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Herceptin is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin [see Dosage and Administration (2.2) ] . 1.2 Metastatic Breast Cancer Herceptin is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin [see Dosage and Administration (2.2) ] . 1.3 Metastatic Gastric Cancer Herceptin is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-authorized companion diagnostic for...

Mechanism: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro , Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • HERCEPTIN · TRASTUZUMAB 21MG/ML · VIAL, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trastuzumab" as an intervention, any sponsor and status, largest first.

All 1,500 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea6,727
  • alopecia5,032
  • nausea4,582
  • fatigue4,414
  • off label use4,273
  • death3,634
  • disease progression3,611
  • myelosuppression3,242
  • vomiting3,054
  • dyspnoea2,795
  • pyrexia2,541
  • asthenia2,348

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004372
2005377
2006529
2007587
2008654
2009973
20101,225
20111,190
20122,644
20132,889
20142,389
20152,682
20162,839
20174,453
20185,684
20194,963
20205,107
20214,903
20224,743
20235,016
20246,903
20254,330
20263,067

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Herceptin (Trastuzumab)

2024 spending

$4.7M

Beneficiaries

122

919 claims

Per beneficiary

$38,467

$1,505.59 per unit

View as table
YearSpending
2020$11,712,224
2021$8,175,872
2022$5,953,812
2023$4,383,515
2024$4,692,925

Part B: Herceptin (Trastuzumab) · HCPCS J9355

2024 spending

$92.6M

Beneficiaries

2,840

24,605 claims

Per beneficiary

$32,612

2024 ASP limit $79.13 per unit

View as table
YearSpending
2020$461,739,445
2021$223,709,771
2022$155,340,135
2023$108,679,973
2024$92,619,460

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,899 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.